Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 501–600 of 673
Hayashida, Y., Kondo, H., & González, C. (2006) · Advances in experimental medicine and biology · doi:10.1007/0-387-31311-7 · Cited by 13
Kocemba‐Pilarczyk, K. A., Ostrowska, B., Trojan, S., Aslan, E., Kusior, D., Lasota, M., Lenouvel, C., & Dulińska-Litewka, J. (2018) · Acta Biochimica Polonica · doi:10.18388/abp.2017_1630 · Cited by 16
“…to current knowledge, besides the classical oxygen-dependent regulators of HIF-1 activity, the chaperone heat shock protein 90 (HSP90) was shown to stabilize HIF-1 alpha subunit in oxygen-independent manner, protecting it from proteasomal degradation (Isaacs et al., 2002; Koh and Powis, 2012).”
BackgroundPagoulatos, D., Pharmakakis, N. M., Lakoumentas, J., & Assimakopoulou, M. (2014) · PubMed Central · Cited by 15
Parveen, S. M. A., Natani, S., Sruthi, K. K., Khilar, P., & Ummanni, R. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106232 · Cited by 12
Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy
de Keijzer, M. J., de Klerk, D. J., de Haan, L. R., van Kooten, R. T., Franchi, L. P., Dias, L. M., Kleijn, T. G., van Doorn, D. J., Heger, M., & on behalf of the Photodynamic Therapy Study Group (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2099-1_19 · Cited by 14
HIF-1 inhibitors as anti-cancer therapy
Mooring, S. R., & Wang, B. (2011) · Science China Chemistry · doi:10.1007/s11426-010-4187-5 · Cited by 15
The Importance of Pathology and Genetics for the Diagnosis and Therapy of Renal Cell Carcinoma
Störkel, S., Kristiansen, G., & Moch, H. (2007) · European Urology Supplements · doi:10.1016/j.eursup.2007.03.004 · Cited by 12
“Targeting the transcription factor HIF directly is difficult, but a variety of agents have been identified that down-regulate HIF-a levels indirectly, for example, inhibitors targeting the mammalian target of rapamycin (mTOR) or heat shock protein 90 (HSP90) [29,30].”
BackgroundFine tuning of the transcription juggernaut: A sweet and sour saga of acetylation and ubiquitination
Ghosh, A., Chakraborty, P., & Biswas, D. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194944 · Cited by 12
Wang, R., Zhang, P., Li, J., Guan, H., & Shi, G. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.005 · Cited by 14
Discovery and Development of Tumor Angiogenesis Assays
Natale, G., & Bocci, G. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2703-7_1 · Cited by 14
SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities
Dominguez, C. E., Cunningham, D., & Chandler, D. S. (2017) · Human Genetics · doi:10.1007/s00439-017-1835-2 · Cited by 13
Gomes, J. S., Sene, L. D. B., Lamana, G. L., Boer, P. A., & Gontijo, J. A. R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0266293 · Cited by 10
“has been demonstrated that a fall in HSP90 expression decreases in HIF-1α tissue levels, promoting a reduction in its transposition to the cell nucleus and binding in target genes [43-47].”
Kim, M. J., Ku, J. M., Choi, Y., Lee, S.-Y., Hong, S. H., Kim, H. I., Shin, Y. C., & Ko, S. (2022) · Molecules · doi:10.3390/molecules27072106 · Cited by 13
Parathyroid hormone regulation of hypoxia-inducible factor signaling in osteoblastic cells
Wong, A., Loots, G. G., Yellowley, C. E., Dosé, A. C., & Genetos, D. C. (2015) · Bone · doi:10.1016/j.bone.2015.07.002 · Cited by 11
Kim, C., Park, C., Kim, E. J., & Nam, Y. K. (2020) · Aquaculture Reports · doi:10.1016/j.aqrep.2020.100566 · Cited by 13
iTRAQ: a method to elucidate cellular responses to mycotoxin zearalenone
Gazzah, A. C., Camoin, L., Abid, S., Bacha, H., & Ladjimi, M. M. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.1766 · Cited by 10
Braliou, G. G., Venieris, E., Kalousi, A., & Simos, G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.043 · Cited by 15
Interactions Between Non-Coding RNAs and HIF-1alpha in the Context of Colorectal Cancer
Gong, L., Zhang, H., Liu, Y., Wang, X., & Xia, R. (2025) · Biomolecules · doi:10.3390/biom15040510 · Cited by 10
“Additionally, the downregulation of miR-210-3p augments oxidative phosphorylation (OXPHOS).”
HSF-1, HIF-1and HSP90 expression on recombinant Pichia pastoris under fed-batch fermentation
Zepeda, A. B., Figueroa, C. A., Abdalla, D. S. P., Maranhão, A. Q., Ulloa‐Rodríguez, P., Pessoa, A., & Farías, J. G. (2014) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822014000200015 · Cited by 9
“Under certain conditions, HIF-1 can also be subjected to VHL- and oxygen-independent degradation (Mabjeesh et al., 2002; Isaacs et al., 2002).”
Sojka, D. R., Gogler‐Pigłowska, A., Kania, D., Vydra, N., Wiecha, K., Adamiec‐Organiściok, M., Wilk, A., Chumak, V., Matysniak, D. P., & Ścieglińska, D. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119735 · Cited by 11
Kadonosono, T., Kuchimaru, T., Yamada, S., Takahashi, Y., Murakami, A., Tani, T., Watanabe, H., Tanaka, T., Hirota, K., Inoue, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026640 · Cited by 14
Schwock, J., Geddie, W. R., & Hedley, D. W. (2005) · Cytometry Part A · doi:10.1002/cyto.a.20192 · Cited by 9
“Similarly, some studies report a degradation of HIF1a after Hsp90 inhibition (40), whereas others show merely a delayed accumulation of the protein (25) or an inhibition of the transcriptional activity (41).”
BackgroundIs Hypoxic/Altitude Training an Important Topic in the Field of Hypoxia?
Millet, G. P., Burtscher, M., & Burtscher, J. (2021) · Journal of Science in Sport and Exercise · doi:10.1007/s42978-021-00144-y · Cited by 8
Analysis of differently expressed proteins involved in metastatic niche of lung
Zheng, Y., Lin, Y., Situ, D., Jiang, L., Su, X., & Long, H. (2013) · Thoracic Cancer · doi:10.1111/1759-7714.12033 · Cited by 8
Wang, Y., Li, Y., Wang, D., Li, Y., Chang, A. B., & Chan, W. K. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.037 · Cited by 8
“Thus there is an immense interest in limiting the cellular HIF-1a function via various mechanisms such as (1) suppression of its message levels using a HIF-1a-targeting antisense oligonucleotide [28]; (2) suppression of its protein synthesis by topoisomerase inhibitors [29]; (3) promotion of its protein degradation by…”
BackgroundSchaefer, S., Svenstrup, T. H., Fischer, M., & Guerra, B. (2017) · Pharmaceuticals · doi:10.3390/ph10010005 · Cited by 10
Hypoxia Regulation of Stem Cell
Liu, Y., Tsai, A., Yuan, X., Li, Y., & Ma, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802734-9.00018-4 · Cited by 8
Ghasemishahrestani, Z., Mattos, L. M. M., Tilli, T. M., dos Santos, A. L. S., & Pereira, M. D. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200819123357 · Cited by 7
Regulation of hypoxia-inducible factor 1 (HIF-1) by nitric oxide in oral squamous cell carcinoma
Brennan, P. A., & Quintero, M. (2005) · Annals of The Royal College of Surgeons of England · doi:10.1308/147870805x28163 · Cited by 7
Heidarian, Y., Fasteen, T. D., Mungcal, L., Buddika, K., Mahmoudzadeh, N. H., Nemkov, T. G., D’Alessandro, A., & Tennessen, J. M. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102106 · Cited by 8
A cardiac fibroblast-enriched micropeptide regulates inflammation in ischemia/reperfusion injury
Yan, Y., Zhang, T., He, X., Du, T., Dai, G., Xu, X., chen, Z., Wu, J., Zhou, H., Peng, Y., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187848 · Cited by 5
Grimes, C. J., Petersen, L. H., & Schulze, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-90540-9 · Cited by 8
The Critical Role of Hypoxia in Tumor-Mediated Immunosuppression
Aouali, N., Bosseler, M., Sauvage, D., Moer, K. V., Berchem, G., & Janji, B. (2017) · InTech eBooks · doi:10.5772/65383 · Cited by 7
Inhibitors of Tumor Angiogenesis
Harris, A. L., & Generali, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00010-3 · Cited by 7
Yoshikawa, N., Nemoto, T., Satoh, S., Maruta, T., Yanagita, T., Chosa, E., & Wada, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.08.013 · Cited by 6
Khouzam, R. A., Salman, S., Thiery, J., Zaarour, R. F., Vela, V., Limani, P., Janji, B., & Chouaïb, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093873 · Cited by 7
Boticario, C. B., & Angosto, M. C. (2010) · Anales de la Real Academia Nacional de Farmacia · Cited by 11
HSP90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation
Lawag, A. A., Napper, J. M., Hunter, C. A., Bacon, N. A., Deskins, S., El-hamdani, M., Govender, S.-L., Koc, E. C., & Sollars, V. E. (2017) · Cellular Reprogramming · doi:10.1089/cell.2017.0001 · Cited by 5
Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA
Dominguez, C. E., Cunningham, D., Venkataramany, A. S., & Chandler, D. S. (2022) · Human Genetics · doi:10.1007/s00439-021-02408-7 · Cited by 5
Jensen, C. C., & Warfel, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00039-6 · Cited by 5
Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy
Rapisarda, A., & Melillo, G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_1 · Cited by 6
von Hippel–Lindau-associated malignancies: Mechanisms and therapeutic opportunities
Kaelin, W. G. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.04.003 · Cited by 8
Zhong, H., Wang, R., Kelavkar, U. P., Wang, C. Y., & Simons, J. W. (2014) · Cancer Medicine · doi:10.1002/cam4.227 · Cited by 5
Karsikas, S. (2015) · Cited by 4
Trübenbach, K., da Costa, G., Ribeiro-Silva, C., Mesquita-Ribeiro, R., CORDEIRO, C. A., & Rosa, R. (2013) · Marine Biology · doi:10.1007/s00227-013-2360-z · Cited by 5
“However, many of the Hsp90-regulated/stabilized coproteins that have been discovered to date are involved in signal transduction such as the hypoxia inducible factor 1 α (HIF-1α; Minet et al. 1999; Isaacs et al. 2002; Falsone et al. 2005), which, after dimerization with the β-unit (arnT) in the nucleus, activates spec…”
BackgroundYum, S., Park, H., Hong, S., Jeong, S., Kim, W., & Jung, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.081 · Cited by 5
Self-citationTrigo, J. M., & Bellmunt, J. (2008) · Medicina Clínica · doi:10.1157/13117476 · Cited by 5
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma
Massari, F., Ciccarese, C., Porcaro, A. B., Ferrero, S., Gazzano, G., Artibani, W., Modena, A., Bria, E., Sava, T., Caliò, A., et al. (2014) · Pathology · doi:10.1097/pat.0000000000000150 · Cited by 4
Natural Products as Probes of Selected Targets in Tumor Cell Biology and Hypoxic Signaling
Nagle, D. G., & Zhou, Y. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00054-x · Cited by 5
HIF inhibition: Current strategies and clinical challenges
Więch-Walów, A., Bartoszewska, S., Barton, A., Czechowicz, P., Dudzik, J., Wielockx, B., Collawn, J. F., & Bartoszewski, R. (2026) · Redox biology · doi:10.1016/j.redox.2026.104220 · Cited by 3
“Chaperone systems integrate with these ubiquitin circuits: HSP90 preserves HIF-1 α folding and stability, whereas competition with RACK1 promotes ubiquitin-dependent degradation independently of pVHL, a balance that can be shifted pharmacologically [182,183].”
Alem, F., Brahms, A., Terasaki, K., Omole, S., Kehn‐Hall, K., Schmaljohn, C. S., Bavari, S., Makino, S., & Hakami, R. M. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1331755 · Cited by 3
The hypoxic tumor microenvironment: Functional and metabolic reprogramming of key immune populations
Ojaroodi, A. F., Shokravi, S., Eskandarzadeh, S., Ghahremanzadeh, A., Alizadeh, F., Amirikar, F., Mobayen, G., Mahrooghi, D., Lahouty, M., Shamsasenjan, K., et al. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156443 · Cited by 8
Whalen, K., & Freeman, B. (2026) · Cell stress & chaperones (Print) · doi:10.1016/j.cstres.2026.100190 · Cited by 3
Seagroves, T. N. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0131-6_16 · Cited by 3
Defining the mechanisms underlying cyclin dependent kinase control of HIF-1α
Warfel, N. A. (2022) · Oncotarget · doi:10.18632/oncotarget.28208 · Cited by 3
The Chick Embryo Aortic Arch Assay
Auerbach, R., & Muthukkaruppan, V. (2012) · Springer eBooks · doi:10.1007/978-94-007-4581-0_8 · Cited by 3
Molecular Biology of Kidney Cancer
Kaelin, W. G. (2011) · Springer eBooks · doi:10.1007/978-3-642-21858-3_3 · Cited by 3
The Involvement of the ERK-Hypoxia-Angiogenesis Signaling Axis and HIF-1 in Hepatocellular Carcinoma
Mylonis, I., & Simos, G. (2012) · InTech eBooks · doi:10.5772/30086 · Cited by 5
“Protein interactions like binding to the molecular chaperone HSP90 can increase HIF-1┙ stability by inhibiting VHL-independent degradation (Isaacs et al., 2002; Katschinski et al., 2004).”
BackgroundTargeting Heat Shock Proteins in Colorectal Cancer
Lee, S. L., Dempsey‐Hibbert, N., Vimalachandran, D., Wardle, T. D., Sutton, P. A., & Williams, J. H. H. (2015) · Heat shock proteins · doi:10.1007/978-3-319-17211-8_17 · Cited by 4
HIF-1-regulated glucose metabolism in the control of apoptosis signaling
Fulda, S. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.3.303 · Cited by 3
HSP90: A Key Player in Metal-Induced Carcinogenesis?
Abreu, P. L., Ferreira, L. M. R., Cunha‐Oliveira, T., Alpoim, M. C., & Urbano, A. M. (2019) · Heat shock proteins · doi:10.1007/978-3-030-23158-3_11 · Cited by 4
Cui, Y., Li, H., Yu, S., Afedo, S. Y., & Bai, X. (2022) · Journal of Molecular Histology · doi:10.1007/s10735-021-10054-6 · Cited by 3
Jiang, L., Jian, J., Zhang, H., & Wu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1656409 · Cited by 2
Yum, S., Choi, J., Hong, S., Park, M. H., Lee, J., Ha, N., & Jung, Y. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.033 · Cited by 2
Self-citationRamaswamy, A., Wei, P. Y., & Pan, F. (2019) · Heat shock proteins · doi:10.1007/978-3-030-03952-3_10 · Cited by 2
Hypoxia-Induced Apoptosis in Cancer Development
Sarkar, S., Sinha, S., Saluja, R., & Kalra, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-0313-9_18 · Cited by 3
Pinard, M., Moursli, A., & Coulombe, B. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2267974 · Cited by 2
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
Arai, H., Yang, Y., Baca, Y., Millstein, J., Denda, T., Ou, F., Innocenti, F., Takeda, H., Kubota, Y., Doi, A., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113914 · Cited by 3
Shao, Y., Miura, K., Asawa, Y., Morita, T., Li, G., & Nakamura, H. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00022 · Cited by 2
Panaxadiol acts as an HIF-1α inhibitor to suppress H9N2-induced inflammation
Xu, J., Tao, L., Zhang, M., & Wang, S. (2025) · Veterinary Microbiology · doi:10.1016/j.vetmic.2025.110695 · Cited by 3
Neckers, L. (2022) · Oncotarget · doi:10.18632/oncotarget.28166 · Cited by 2
Self-citationExploiting “Hif Addiction” For Cancer Therapy
Fer, N. D., & Rapisarda, A. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9167-5_14 · Cited by 2
Therapeutic Strategies that Target the HIF System
Cook, K. M., & Schofield, C. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_32 · Cited by 2
Heat Shock Protein 90 and the Proteasome
Neckers, L., & Mollapour, M. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00056-1 · Cited by 3
Self-citationAnimal Models for Angiogenesis on Cancer Research
Makwana, S. H., & Mandal, C. C. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_21 · Cited by 2
HIF2 Inhibition for von-Hippel Lindau Associated Kidney Cancer: Will Urology Lead or Follow?
Shuch, B. M. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.01.018 · Cited by 2
Nagle, D. G., & Zhou, Y. (2012) · Springer eBooks · doi:10.1007/978-90-481-3834-0_22 · Cited by 4
New pathogenic mechanisms in diabetic wound healing
Sunkari, V. G. (2012) · Figshare · Cited by 2
Gene Promoters and Transcription Control Regions as Therapeutic Targets
Zorzano, A., Sebastián, D., Sánchez, J., Miret‐Casals, L., & Alberício, F. (2012) · Wiley eBooks · doi:10.1002/9781118185537.ch9 · Cited by 2
Murthy, S., & Winkler, J. (2002) · Inflammation Research · doi:10.1007/bf02684004 · Cited by 3
Kataria, N., Kerr, B., Zaiter, S. S., McAlpine, S. R., & Cook, K. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/521989 · Cited by 2
Alkhawaja, B. A., Khaleel, A., Dayyih, W. A., Hamad, M. F., Hajjo, R., & Hailat, M. M. (2023) · F1000Research · doi:10.12688/f1000research.130888.1 · Cited by 1
Yang, Y., Ning, X., Chen, M., Gao, K., Guo, T., Zhou, L., Zeng, B., & Zhou, W. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11370-9 · Cited by 2
Clow, T. M., Borowiec, B. G., & Craig, P. M. (2025) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2025.111180 · Cited by 1
Heritz, J. A., Backe, S. J., Pacherille, A., Cayaban, S. J., Basin, M. F., Smith, B. M., Sager, R., Daneshvar, M., Post, D. E., Woodford, M. R., et al. (2026) · Communications Medicine · doi:10.1038/s43856-025-01356-x · Cited by 1
The role of hypoxia-inducible factor-1α in COPD
Zhang, L., Huang, S., Wang, Z. P., Huang, P., Pang, X., Zeng, X., & Liu, X. (2026) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2026.106974 · Cited by 2
Regulation of Cancer Cell Metabolism by Hypoxia
Pulkoski‐Gross, A., Evensen, N. A., & Cao, J. P. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_4 · Cited by 1
Effects of Molecularly Targeting Hypoxia in Oncology
Fiorentini, G., Aliberti, C., Benea, G., Montagnani, F., Mambrini, A., Ballardini, P. L., Cantore, M., & Guadagni, S. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9576-4_7 · Cited by 1
The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies
Kaelin, W. G., & George, D. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-332-5_5 · Cited by 1
Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia
Elias, H. K., & Verma, A. K. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.713482 · Cited by 1
Dual Targeting of Retinal Vasculature in the Mouse Model of Oxygen Induced Retinopathy
DeNiro, M. (2011) · The Open Diabetes Journal · doi:10.2174/1876524601104010060 · Cited by 1
“For example, heat shock protein-90 (HSP90) is a molecular chaperone involved in the folding of HIF-1 protein [80, 81].”
BackgroundTHE VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN AND KIDNEY CANCER
Kaelin, W. G., & Ma, B. (2007) · Medicina-buenos Aires · Cited by 1
Natural Products as Inhibitors of Hypoxia-Inducible Factor-1
Nagle, D. G., & Zhou, Y. (2011) · CRC Press eBooks · doi:10.1201/b11196-8 · Cited by 1
Animal Models for Angiogenesis on Cancer Research
Makwana, S. H., & Mandal, C. C. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_21-1 · Cited by 1
The Immunohistochemical Landscape of the Hypoxia-Related Proteins in Oral Squamous Cell Carcinoma
Lorenzo‐Pouso, A. I., González‐Moles, M. Á., Ramos‐García, P., & Pérez‐Sayáns, M. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_15 · Cited by 1
Non-canonical approaches to targeting hypoxic tumors.
Zhao, S., & El‐Deiry, W. S. (2022) · PubMed Central · Cited by 2
Marine Natural Products Targeting Tumor Microenvironment
Kotoku, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-1714-3_3 · Cited by 1
HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment
Rathmell, W. K. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_3 · Cited by 1
Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis
Hascoët, P., Chesnel, F., Goff, C. L., Goff, X. L., & Arlot‐Bonnemains, Y. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00241 · Cited by 3
Molecular Chaperones and How Addiction Matters in Cancer Therapy
Guzmán, M. L., Lowery, M. A., Taldone, T., Koren, J., Gomes-DaGama, E. M., & Chiosis, G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_7 · Cited by 1
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.